Biome Australia Ltd · ASX:BIO
Biome Australia — Investor Presentation (March 2023)
25 slides from Biome Australia's investor presentation, Mar 6, 2023
Slide 1: Biome Australia Limited Investor Presentation: H1 FY23
Biome Australia Limited Commercial in confidence Investor Presentation: H1 FY23 Blair Norfolk, CEO BIOME AUSTRALIA.COM Douglas Loh, CFO
Slide 2: Disclaimer
Disclaimer This presentation and the information contained within it (the Past performance information included in this presentation The recipient must, and agrees with the Company that “information”) has been prepared solely for the use and is provided for illustrative purposes only, should not be
Slide 3: Our mission
Our mission To prevent disease, improve health outcomes and quality of life, and make our products accessible to all Commercial in confidence
Slide 4: About Biome Australia
About Biome Australia Biome Australia (ASX: BIO) is focused on becoming a global leader in the complementary medicine industry, offering clinically-proven condition-specific probiotic products fueled by novel clinical research programs to cement and extend the evidence base of its probiotic products
Slide 5: Investment and Business Highlights
01 PAGE 5 Practitioner-only probiotics Investment and Business Highlights ACTIVATEDPROBIOTICS.COM.AU Commercial in confidence
Slide 6: H1 FY23 Business Highlights
H1 FY23 Business Highlights PAGE 6 Practitioner-only probiotics Financial performance H1 sales of $3.4m – up 87.5% (vs pcp) Cash receipts from customers of $3.1m ACTIVATEDPROBIOTICS.COM.AU FY23 revenue target of $7.0m Net cash flows from operations of $1.4m Cash balance $3.7m Gross Margin improved t
Slide 7: H1 FY23 Sales Growth
H1 FY23 Sales Growth Commercial in confidence
Slide 8: H1 FY23 Business Highlights
H1 FY23 Business Highlights Widespread distribution Over 3,000 distribution points in Australia, with sales of Activated Probiotics also in the UK & NZ – 50% increase since November 30 2021 IPO Signed Priceline Pharmacy Distribution Agreement – 370 high volume service based pharmacies launched in Q2
Slide 9: H1 FY23 Key Stats - Successes
H1 FY23 Key Stats - Successes PAGE 9 Practitioner-only probiotics Key Performance Indicators Over 3,000 distribution points following Average shopper - 1.8 units per transaction ACTIVATEDPROBIOTICS.COM.AU successful launch with Priceline Pharmacy and 6 visits per year in pharmacy (TWCM data) Activat
Slide 10: Range
02 Range Activated Probiotics Commercial in confidence ACTIVATEDPROBIOTICS.COM.AU Practitioner-only probiotics PAGE 10
Slide 11: Activated Probiotics
Biome DailyTM Biome IBSTM Activated Probiotics DIGESTIVE To help enhance immune To relieve the symptoms of HEALTH system function and promote medically diagnosed IBS healthy digestion Practitioners & Pharmacies Biome Her Biome Prenatal+TM CONSUMER BENEFITS To help maintain a healthy To support a hea
Slide 12: Clinical Research
03 Clinical Research Commercial in confidence ACTIVATEDPROBIOTICS.COM.AU Practitioner-only probiotics PAGE 12
Slide 13: Clinical pipeline - Indication overview
Clinical pipeline - Indication overview ● Three ongoing clinical trials and further research opportunities in discussion BIOME LIFT BIOME KIDS BIOME OSTEO Assessing the efficacy of the Biome Lift™ Analysing the influence of probiotic use on Examining the effect of 12-month absenteeism and immune hea
Slide 14: Biome Eczema Probiotic - Patient Results
Biome Eczema Probiotic - Patient Results “Jude and his mum has said thank you so much. They had tried every skin cream/soap/tablet and nothing has worked up until now. If you recall, Jude told one of the boys at school who asked what was wrong with his skin that he didn’t need to worry because soon
Slide 15: Biome Eczema Probiotic - Patient Results
Biome Eczema Probiotic - Patient Results
Slide 16: New product development
04 New product development Commercial in confidence ACTIVATEDPROBIOTICS.COM.AU Practitioner-only probiotics PAGE 19
Slide 17: Biome Dental Probiotic
Biome Dental™ Probiotic To help support dental health and a healthy oral microbiome Clinically trialled formulation supported by 8 human trials Guaranteed potency The global periodontal disease treatment market was valued at USD 7.6 billion in 2021 and is expected to reach USD 12.2 billion by the en
Slide 18: Key Product Research
Key Product Research The probiotic formulation in Biome Dental was compared to placebo and chlorhexidine mouthwash (standard treatment) in 60 healthy children. A significant decrease of plaque score and gingival index was seen on day 3 compared to placebo, and after 14 days of intake, these results
Slide 19: Biome Recovery Probiotic
Biome Recovery™ Probiotic To help reduce muscle inflammation and recovery time following exercise Clinically trialled formulation Microbac™ technology: 5x more effective delivery Guaranteed potency The AU sports supplement category was worth AUD 1.4 billion in 2021. APAC is currently the fastest grow
Slide 20: Key Product Research
Key Product Research A double-blind, randomised, placebo-controlled trial investigated the effect of the probiotic formulation in Biome RecoveryTM Probiotic on physical performance and levels of inflammation following muscle-damaging exercise in healthy men. After 3 weeks of supplementation, the pro
Slide 21: Biome Lax Probiotic
Biome Lax™ Probiotic To help promote bowel regularity and reduce bloating Clinically trialled formulation Microbac™ technology: 5x more effective delivery Guaranteed potency The global constipation treatment market size was valued at USD 17.04 billion in 2020 and is projected to reach USD 29.04 Bill
Slide 22: Key Product Research
Key Product Research In a double-blind, randomised, placebo-controlled study across 5 years in over 300 subjects, the product formulation in Biome Lax was found to significantly improve the frequency of bowel movements, consistency of stool, ease of evacuation, sensation of complete emptying, and ab
Slide 23: December Half Financial Highlights
05 December Half Financial Highlights Commercial in confidence ACTIVATEDPROBIOTICS.COM.AU Practitioner-only probiotics PAGE 26
Slide 24: H1 FY23 - Cash flows from operations
H1 FY23 - Cash flows from operations 1H23 to Dec 22 1H22 to Dec 21 Comments $’000 $’000 (vs last Qtr) Sales 3,381 1,803 +87.5% Cash receipts from customers 3,054 1,998 +53% Research and development (160) (53) +202% Product manufacturing and operating costs (1,342) (1,515) -11% Sales, advertising and
Slide 25: Contact details
Contact details: Blair Norfolk, CEO Douglas Loh, CFO e: corporate@biomeaustralia.com Websites: biomeaustralia.com activatedprobiotics.com.au Biome Australia Limited Investor Presentation March 2023 Commercial in confidence